Aspartyl protease inhibitors as anti-filarial drugs

Authors

Liana Beld, University of California, San Francisco
Hyeim Jung, Washington University School of Medicine in St. Louis
Christina A Bulman, University of California, San Francisco
Bruce A Rosa, Washington University School of Medicine in St. Louis
Peter U Fischer, Washington University School of Medicine in St. Louis
James W Janetka, Washington University School of Medicine in St. Louis
Sara Lustigman, New York Blood Center
Judy A Sakanari, University of California, San Francisco
Makedonka Mitreva, Washington University School of Medicine in St. Louis

Journal

Pathogens

Publication Date

6-18-2022

Volume

11

Issue

6

First Page

707

Document Type

Open Access Publication

DOI

10.3390/pathogens11060707

Rights and Permissions

Beld, L.; Jung, H.; Bulman, C.A.; Rosa, B.A.; Fischer, P.U.; Janetka, J.W.; Lustigman, S.; Sakanari, J.A.; Mitreva, M. Aspartyl Protease Inhibitors as Anti-Filarial Drugs. Pathogens 2022, 11, 707. https://doi.org/10.3390/pathogens11060707 This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Beld, Liana; Jung, Hyeim; Bulman, Christina A; Rosa, Bruce A; Fischer, Peter U; Janetka, James W; Lustigman, Sara; Sakanari, Judy A; and Mitreva, Makedonka, "Aspartyl protease inhibitors as anti-filarial drugs." Pathogens. 11, 6. 707 (2022).
https://digitalcommons.wustl.edu/oa_4/10